Clinical trials
Metastatic Pancreatic Adenocarcinoma clinical trials
Below are recruiting metastatic pancreatic adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 249 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06018896RecruitingPhase 2
Vitamin C for late-stage pancreatic cancer quality of life
This trial is testing if high-dose vitamin C can improve quality of life for people with advanced pancreatic cancer that has continued to grow after two previous treatments. It aims to see if vitamin C can help patients feel better and possibly slow the cancer.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06427239RecruitingPhase 1/Phase 2
HRS-4642 and adebrelimab for advanced pancreatic cancer
This trial tests a combination of two drugs (HRS-4642 and adebrelimab) for people with advanced pancreatic cancer that has not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow the disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06842303Recruiting
Using new MRI scans to measure pancreatic tumor response
This study tests whether new MRI techniques can better show how pancreatic cancer responds to treatment. It compares standard CT scans with advanced MRI sequences for patients whose cancer has not spread.
Vandœuvre-lès-Nancy, FranceAges 18 years+ - NCT07483983RecruitingPhase 2
Study of ASP3082 for advanced lung and pancreatic cancers with KRAS G12D mutation
This trial tests a new drug, ASP3082, for people with advanced non-small cell lung cancer or pancreatic cancer that has a specific gene change called KRAS G12D. The study will collect tumor and blood samples to understand how the cancer responds or becomes resistant to the treatment.
Villejuif, FranceAges 18 years+ - NCT06789679RecruitingPhase 2
Adding S-1 to standard chemo for advanced pancreatic cancer
This trial tests whether adding a third drug (S-1, a chemotherapy pill) to the standard two-drug IV chemo (albumin-bound paclitaxel and gemcitabine) can help people with advanced pancreatic cancer live longer. It's for those who haven't had treatment yet for their advanced cancer.
Beijing, Chaoyang DistrictAges 18 years+ - NCT05752812Recruiting
HELPP score study for pancreatic cancer outcomes
This study looks at a pretreatment score (called the HELPP score) to predict survival in people with localized pancreatic ductal adenocarcinoma. It may help doctors better estimate outcomes based on information gathered before treatment.
ViennaAges 18–99 - NCT07444541RecruitingPhase 1/Phase 2
Study of ANO31905 plus chemo for CLDN18.2-positive pancreatic cancer
This trial tests a new drug called ANO31905 added to standard chemotherapy for people with advanced pancreatic cancer that has a specific protein called CLDN18.2 on its cells. The study aims to see if the combination works better than chemo alone.
Los Angeles, CaliforniaAges 18 years+ - NCT05403554RecruitingPhase 1
Testing a new mesothelin-targeting drug for certain solid cancers
This Phase 1 study tests NI-1801, a drug designed to attach to a target on cancer cells (mesothelin). It may be given alone or with pembrolizumab to help shrink tumors in advanced cancers that have enough mesothelin on their cells.
ParisAges 18 years+ - NCT06767813RecruitingPhase 2
Study of TQB2868, anlotinib, and chemo for first-line pancreatic cancer
This trial tests a new combination of drugs (TQB2868, anlotinib, and chemotherapy) as a first treatment for metastatic pancreatic cancer that has spread. It may help if you have not had prior treatment for advanced disease.
Zhengzhou, HenanAges 18–75 - NCT06941857RecruitingPhase 2
Immunotherapy plus chemotherapy for advanced pancreatic cancer
This trial tests a new combination of drugs (NC410 plus chemotherapy and nivolumab, with or without ipilimumab) for people with metastatic pancreatic cancer who haven't had treatment yet. The goal is to see if adding these immunotherapy agents can help shrink or control the tumor.
Baltimore, MarylandAges 18 years+ - NCT06953999RecruitingPhase 3
Testing immunotherapy plus chemo for metastatic pancreatic cancer
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
Harbin, HeilongjiangAges 18–75 - NCT07481383RecruitingPhase 1
Implant device for chemo delivery in advanced pancreatic cancer
This trial tests an implantable device that delivers chemotherapy (gemcitabine) directly to pancreatic tumors. It may offer a new treatment option for people with non-metastatic, advanced pancreatic cancer that cannot be surgically removed.
Ann Arbor, MichiganAges 18 years+ - NCT06005493RecruitingPhase 1/Phase 2
Study of AZD5863 for advanced stomach, esophagus, or pancreatic cancer
This trial is testing an investigational drug called AZD5863 for people whose stomach, esophagus, or pancreatic cancer has spread and hasn't responded to at least one previous treatment. The study aims to see if targeting a protein called Claudin 18.2 on tumor cells can help shrink or slow the cancer.
Jacksonville, FloridaAges 18 years+ - NCT05132244Recruiting
Checking and treating blood sugar in pancreatic cancer
This trial tests a plan to monitor and manage blood sugar in people with pancreatic ductal cancer who are starting a specific chemotherapy regimen (FOLFIRINOX). The goal is to prevent or address high blood sugar during treatment, which may help people stay on therapy safely.
Vancouver, British ColumbiaAges 18 years+ - NCT07340151Recruiting
Surgery for limited liver or lung pancreatic cancer spread
This trial tests whether removing or ablating limited liver or lung tumors from pancreatic cancer that has not spread elsewhere, along with a specific chemotherapy (NALIRIFOX), can help patients. It is for people who have not had any previous cancer treatment.
San Antonio, TexasAges Any age - NCT03492671RecruitingPhase 2
Two chemotherapy drugs plus radiation before pancreatic surgery
This trial tests whether giving two already-approved chemotherapy drugs and radiation before surgery works better for localized pancreatic cancer. It’s meant for people whose cancer looks removable by surgery and who haven’t had prior pancreatic cancer treatment.
Loma Linda, CaliforniaAges 18 years+ - NCT07529808RecruitingPhase 1/Phase 2
New Drug BHB810 for Advanced Stomach Cancer
This trial tests a new drug called BHB810 for gastric (stomach) and gastroesophageal junction cancer that has stopped responding to standard treatments or has no standard options available. The drug targets a protein called CDH17 found on cancer cells and may help slow or shrink the tumor.
Fairfax, VirginiaAges 18 years+ - NCT07644559RecruitingPhase 2
VS-7375 for KRAS G12D pancreatic cancer
This study tests a new drug called VS-7375, combined with cetuximab, for pancreatic cancer patients whose tumors have a specific genetic mutation called KRAS G12D. The goal is to see if this combination can shrink tumors and help patients live longer.
Los Angeles, CaliforniaAges 18 years+ - NCT07199764RecruitingPhase 2
Maintenance therapy using combination immunotherapy for pancreatic cancer
This trial tests a combination of immunotherapy drugs (targeting CD40 and other immune cells) as a maintenance treatment for people with advanced pancreatic cancer that has not grown or has shrunk after initial chemotherapy. The goal is to see if this approach can keep the cancer from progressing longer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07683845Recruiting
Using a tumor model to predict chemo response in pancreatic cancer
This trial tests a personalized approach by growing a miniature model of your tumor from a tissue sample. The goal is to see if this model can predict which chemotherapy will work best for you before you start treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07255404RecruitingPhase 2
Testing pumitamig with chemotherapy for untreated pancreatic cancer
This trial tests an experimental drug called pumitamig combined with standard chemotherapy for people with advanced pancreatic cancer that has spread and has not been treated yet. The goal is to see if this combination is safe and effective.
Bedford ParkAges 18 years+ - NCT05132504RecruitingPhase 2
Pre-surgery chemotherapy and immunotherapy for operable pancreatic cancer
This Phase 2 trial tests giving chemotherapy plus pembrolizumab (an immunotherapy) before surgery, to shrink or control potentially removable pancreatic cancer. The goal is to improve outcomes while making sure the cancer can still be safely removed by surgery.
Houston, TexasAges 18 years+ - NCT06639724RecruitingPhase 1
Test of fostamatinib with chemo before and after surgery for pancreatic cancer
This trial tests adding a new drug, fostamatinib, to standard chemotherapy before and after surgery for pancreatic cancer that can be removed. The goal is to see if the combination helps reduce the chance of cancer coming back.
La Jolla, CaliforniaAges 18 years+ - NCT07033689RecruitingEarly Phase 1
Testing Suizenji for newly diagnosed pancreatic cancer
This trial tests a new ultrasound treatment called Suizenji for people with pancreatic cancer that cannot be removed by surgery. The goal is to see if it can safely target the tumor.
San Francisco, CaliforniaAges 18 years+
Hear when a new Metastatic Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic pancreatic adenocarcinoma?
- Yes. Clin2 currently lists 249 recruiting metastatic pancreatic adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic pancreatic adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic pancreatic adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.